Does Vanzacaftor Tezacaftor And Deutivacaftor Interact with Breast Cancer Resistance Protein Bcrp Substrates?
Vanzacaftor Tezacaftor And Deutivacaftor and Breast Cancer Resistance Protein Bcrp Substrates have a moderate drug interaction according to U.S. FDA drug labeling data. Monitor more frequently for adverse reactions. Vanzacaftor and deutivacaftor are BCRP inhibitors in vitro that may increase exposure of BCRP substrates. The mechanism involves bcrp inhibition may increase substrate exposure. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Moderate
- Vanzacaftor Tezacaftor And Deutivacaftor Class
- Cystic Fibrosis Transmembrane Conductance Regulator Potentiator
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Vanzacaftor Tezacaftor And Deutivacaftor and Breast Cancer Resistance Protein Bcrp Substrates occurs because bcrp inhibition may increase substrate exposure. Clinically, this means monitor more frequently for adverse reactions. vanzacaftor and deutivacaftor are bcrp inhibitors in vitro that may increase exposure of bcrp substrates. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.
What To Tell Your Doctor or Pharmacist
If you are taking Vanzacaftor Tezacaftor And Deutivacaftor and your doctor is considering prescribing Breast Cancer Resistance Protein Bcrp Substrates (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider